Eric M. Gale
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eric M. Gale has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Peter Caravan
Athinoula A. Martinos Center for Biomedical Imaging
24 shared publications - Veronica Clavijo Jordan
Athinoula A. Martinos Center for Biomedical Imaging
15 shared publications - Mozhdeh Sojoodi
Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
12 shared publications - Ian Ramsay
Department of Radiology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts
11 shared publications - Kenneth K. Tanabe
Massachusetts General Hospital 1 Boston, MA
11 shared publications - Motaz Qadan
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA
11 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
Magnetic Resonance Silent Activatable Probe with Massive Signal Amplification for Rapid Detection of Inflammation-Associated Fibrogenesis
Biomarker-specific molecular imaging is vital in precision medicine. However, a fundamental challenge of most molecular imaging methods is the difficulty of distinguishing specific molecular signal from nonspecific signal arising from the distribution of the molecular probe. This is even more pronounced in metabolically active organs such as the kidney and liver where the probe may concentrate prior to elimination. As a result, almost all molecular imaging relies on delayed imaging to achieve specificity, but this constrains clinical throughput and impedes rapid assessment of the diseased organ. Here, we report a magnetic resonance (MR) probe, Fe(II)-IAFP2, which combines 3 drivers of relaxivity enhancement to decouple disease specificity from probe distribution. Fe(II)-IAFP2 is MR-silent in its Fe(II) state, producing negligible MR signal even at high concentrations. In inflammatory, fibrogenic microenvironments common to many diseases, rapid oxidation to Fe(III) activates MR enhancement, while reversible aldehyde-mediated binding to remodeled extracellular matrix further amplifies relaxivity and promotes retention at the site of tissue injury. This dual activation–retention mechanism enables robust signal generation within minutes of administration. In mouse models of renal and liver fibrogenesis, Fe(II)-IAFP2 generated disease-associated MR contrast within minutes after intravenous administration. Together, this work demonstrates an effective strategy for rapid, activity-based molecular MR imaging through the combination of pathological activation and complementary tissue retention.
- 12 November 2026
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
Open AccessMagnetic Resonance Silent Activatable Probe with Massive Signal Amplification for Rapid Detection of Inflammation-Associated Fibrogenesis
Biomarker-specific molecular imaging is vital in precision medicine. However, a fundamental challenge of most molecular imaging methods is the difficulty of distinguishing specific molecular signal from nonspecific signal arising from the distribution of the molecular probe. This is even more pronounced in metabolically active organs such as the kidney and liver where the probe may concentrate prior to elimination. As a result, almost all molecular imaging relies on delayed imaging to achieve specificity, but this constrains clinical throughput and impedes rapid assessment of the diseased organ. Here, we report a magnetic resonance (MR) probe, Fe(II)-IAFP2, which combines 3 drivers of relaxivity enhancement to decouple disease specificity from probe distribution. Fe(II)-IAFP2 is MR-silent in its Fe(II) state, producing negligible MR signal even at high concentrations. In inflammatory, fibrogenic microenvironments common to many diseases, rapid oxidation to Fe(III) activates MR enhancement, while reversible aldehyde-mediated binding to remodeled extracellular matrix further amplifies relaxivity and promotes retention at the site of tissue injury. This dual activation–retention mechanism enables robust signal generation within minutes of administration. In mouse models of renal and liver fibrogenesis, Fe(II)-IAFP2 generated disease-associated MR contrast within minutes after intravenous administration. Together, this work demonstrates an effective strategy for rapid, activity-based molecular MR imaging through the combination of pathological activation and complementary tissue retention.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Figure S2. Tissue immunohistochemistry of K-rasLSL.G12D/+; Trp53R172H/+; Pdx-1-Cre (KPC) tissue carrying a spectrum of pancreatic disease. H&E (left) and ZIP3 (right) IHC of KPC tissue bearing A) PanIN (II-III) and large tumor, and KPC with pancreas graded as B) normal – PanIN (I-II).
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Figure S2. Tissue immunohistochemistry of K-rasLSL.G12D/+; Trp53R172H/+; Pdx-1-Cre (KPC) tissue carrying a spectrum of pancreatic disease. H&E (left) and ZIP3 (right) IHC of KPC tissue bearing A) PanIN (II-III) and large tumor, and KPC with pancreas graded as B) normal – PanIN (I-II).
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, primarily because of late-stage diagnosis and limited treatment options. Zinc homeostasis is markedly dysregulated in PDAC, and this dysregulation can be probed by administering a secretagogue to stimulate zinc secretion (SSZS) in the exocrine pancreas and imaging with a zinc-sensitive MRI probe. This study demonstrated the potential of SSZS-MRI for sensitive detection, monitoring treatment response, and assessing recurrence after treatment withdrawal in PDAC. The approach relied on interrogating the pancreas, circumventing the challenge of locating small, elusive tumors. SSZS-MRI enabled PDAC detection by observing the unique zinc hypersecretory activity of the pancreas when malignancy was present. PDAC led to dysregulation of zinc transporters in both human and mouse pancreas. Combining secretagogues such as secretin and caerulein maximized zinc secretion and MRI signal in the pancreas. Notably, SSZS-MRI detected treatment responses to KRASG12D inhibition within 3 to 5 days and identified cancer recurrence as early as 1 day after treatment withdrawal. Additionally, secretagogue stimulation improved treatment responses and delayed recurrence in both treatment models. These findings suggest that SSZS-MRI could significantly enhance PDAC diagnosis and management, providing an imaging modality that can help optimize patient outcomes.Significance:Secretagogue-stimulated zinc secretion MRI is effective at detecting pancreatic cancer, monitoring treatment response, and determining cancer recurrence, offering a promising noninvasive imaging tool to improve patient management and outcomes.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, primarily because of late-stage diagnosis and limited treatment options. Zinc homeostasis is markedly dysregulated in PDAC, and this dysregulation can be probed by administering a secretagogue to stimulate zinc secretion (SSZS) in the exocrine pancreas and imaging with a zinc-sensitive MRI probe. This study demonstrated the potential of SSZS-MRI for sensitive detection, monitoring treatment response, and assessing recurrence after treatment withdrawal in PDAC. The approach relied on interrogating the pancreas, circumventing the challenge of locating small, elusive tumors. SSZS-MRI enabled PDAC detection by observing the unique zinc hypersecretory activity of the pancreas when malignancy was present. PDAC led to dysregulation of zinc transporters in both human and mouse pancreas. Combining secretagogues such as secretin and caerulein maximized zinc secretion and MRI signal in the pancreas. Notably, SSZS-MRI detected treatment responses to KRASG12D inhibition within 3 to 5 days and identified cancer recurrence as early as 1 day after treatment withdrawal. Additionally, secretagogue stimulation improved treatment responses and delayed recurrence in both treatment models. These findings suggest that SSZS-MRI could significantly enhance PDAC diagnosis and management, providing an imaging modality that can help optimize patient outcomes.Significance:Secretagogue-stimulated zinc secretion MRI is effective at detecting pancreatic cancer, monitoring treatment response, and determining cancer recurrence, offering a promising noninvasive imaging tool to improve patient management and outcomes.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Figure S3. SSZS MRI of mice with PDAC cell liver metastasis. A) Liver metastasis generated by injection of 106 syngeneic Hy15549 cells directly into the spleen of the mouse. B) In vivo SSZS - MRI of animals 7 days after PDAC cell or saline splenic injection. T1-weighted MRI of the pancreas after 0.07 mmol/kg GdL and 10 µg/kg caerulein and secretin cocktail. C) (left) Dynamic ΔCNR of pancreas vs. muscle. (right) Calculated area under the curve (AUC) of the pancreas of mice bearing liver metastases (N = 3) where the signal change relative to muscle over 30 minutes was integrated and compared with the sham injected animals (N = 1). Error bars are SD.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Figure S3. SSZS MRI of mice with PDAC cell liver metastasis. A) Liver metastasis generated by injection of 106 syngeneic Hy15549 cells directly into the spleen of the mouse. B) In vivo SSZS - MRI of animals 7 days after PDAC cell or saline splenic injection. T1-weighted MRI of the pancreas after 0.07 mmol/kg GdL and 10 µg/kg caerulein and secretin cocktail. C) (left) Dynamic ΔCNR of pancreas vs. muscle. (right) Calculated area under the curve (AUC) of the pancreas of mice bearing liver metastases (N = 3) where the signal change relative to muscle over 30 minutes was integrated and compared with the sham injected animals (N = 1). Error bars are SD.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Figure S5. MRI of unstimulated animals on MRTX1133 treatment and after MRTX1133 treatment withdrawal. (Left) Quantified dynamic change in CNR of tumor-bearing pancreas tissue vs. muscle over time. (Right) Area under the change in CNR over the entire imaging period while on A) MRTX1133 treatment and receiving saline as secretagogue control or after B) MRTX1133 treatment withdrawal. Error bars are SEM. Statistical significance was determined by one-way ANOVA with Tukey test for multiple comparisons.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Figure S5. MRI of unstimulated animals on MRTX1133 treatment and after MRTX1133 treatment withdrawal. (Left) Quantified dynamic change in CNR of tumor-bearing pancreas tissue vs. muscle over time. (Right) Area under the change in CNR over the entire imaging period while on A) MRTX1133 treatment and receiving saline as secretagogue control or after B) MRTX1133 treatment withdrawal. Error bars are SEM. Statistical significance was determined by one-way ANOVA with Tukey test for multiple comparisons.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Figure S1. Stimulated zinc secretion in PDAC mouse of FVB genetic background. A) Orthotopic PDAC cell implantation and imaging schedule. B) (left) Change in contrast to noise ratio (ΔCNR) after zinc probe and caerulein or saline for PDAC animals bearing Han4.13 cell tumors for 1 week and 2 weeks. (right) The area under the curve of pancreas ΔCNR over the entire 27-minute imaging period for all groups. C) Tissue H&E showing the presence of 1-week old and 2-week-old tumors (Arrow pointing PDAC) and IHC panels showing immunostaining against ZIP3, ZIP4, ZNT1, and SMA/MPO as inflammatory markers. Error bars are SEM. Statistical significance was determined by one-way ANOVA with Tukey test for multiple comparisons. *p < 0.05.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Figure S1. Stimulated zinc secretion in PDAC mouse of FVB genetic background. A) Orthotopic PDAC cell implantation and imaging schedule. B) (left) Change in contrast to noise ratio (ΔCNR) after zinc probe and caerulein or saline for PDAC animals bearing Han4.13 cell tumors for 1 week and 2 weeks. (right) The area under the curve of pancreas ΔCNR over the entire 27-minute imaging period for all groups. C) Tissue H&E showing the presence of 1-week old and 2-week-old tumors (Arrow pointing PDAC) and IHC panels showing immunostaining against ZIP3, ZIP4, ZNT1, and SMA/MPO as inflammatory markers. Error bars are SEM. Statistical significance was determined by one-way ANOVA with Tukey test for multiple comparisons. *p < 0.05.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Figure S6. SSZS as treatment during tumor progression. A) 10,000 PDAC Hy14459 cells were implanted into the mouse pancreas and allowed to grow for 15 days. Mice were randomized to receive a combination of either secretagogue or saline and Zn probe or saline. Mice were fasted overnight prior to every treatment. B) Tumor volume was measured from coronal or axial T2-weighted MRI scans. The tumor and necrotic core were identified and measured separately. Error bars are SD. Statistical significance was determined by one-way ANOVA with Tukey test for multiple comparisons. *P < 0.05
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Figure S6. SSZS as treatment during tumor progression. A) 10,000 PDAC Hy14459 cells were implanted into the mouse pancreas and allowed to grow for 15 days. Mice were randomized to receive a combination of either secretagogue or saline and Zn probe or saline. Mice were fasted overnight prior to every treatment. B) Tumor volume was measured from coronal or axial T2-weighted MRI scans. The tumor and necrotic core were identified and measured separately. Error bars are SD. Statistical significance was determined by one-way ANOVA with Tukey test for multiple comparisons. *P < 0.05
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Figure S4. Inflammation in the pancreas with pancreatic duct ligation. A) (Left) In vivo MRI of the inflamed pancreas. The ligated tail and un-ligated head of the pancreas were identified by anatomical T2-weighted MRI scans. Molecular imaging of inflammation in the pancreas was obtained by administering the ROS-active probe FePyC3A. The tail of the pancreas exhibited differential enhancement compared to the head of the pancreas indicating the presence of ROS as a hallmark of a highly inflammatory state in the ligated pancreas. (Right) Calculated area under the curve (AUC) of head and tail of the pancreas in mice after receiving the inflammation sensitive probe FePyC3A. B) (Left) IHC staining against myeloperoxidase (MPO) for both ligated pancreas portions, head, and tail. (Right) Blinded quantification of MPO expression in tissue sections for both pancreatic tissue portions, head, and tail. Error bars are SEM, Statistical significance was obtained by two-tailed t-test. *P < 0.05
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Figure S4. Inflammation in the pancreas with pancreatic duct ligation. A) (Left) In vivo MRI of the inflamed pancreas. The ligated tail and un-ligated head of the pancreas were identified by anatomical T2-weighted MRI scans. Molecular imaging of inflammation in the pancreas was obtained by administering the ROS-active probe FePyC3A. The tail of the pancreas exhibited differential enhancement compared to the head of the pancreas indicating the presence of ROS as a hallmark of a highly inflammatory state in the ligated pancreas. (Right) Calculated area under the curve (AUC) of head and tail of the pancreas in mice after receiving the inflammation sensitive probe FePyC3A. B) (Left) IHC staining against myeloperoxidase (MPO) for both ligated pancreas portions, head, and tail. (Right) Blinded quantification of MPO expression in tissue sections for both pancreatic tissue portions, head, and tail. Error bars are SEM, Statistical significance was obtained by two-tailed t-test. *P < 0.05
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Table S1. Performance evaluation for SSZS-MRI versus RECIST. Diagnostic performance for early (1-3d) measurements by volumetric RECIST, and SSZS MRI show that SSZS MRI discriminates stable from progressive disease more accurately than RECIST at every established threshold.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment
Table S1. Performance evaluation for SSZS-MRI versus RECIST. Diagnostic performance for early (1-3d) measurements by volumetric RECIST, and SSZS MRI show that SSZS MRI discriminates stable from progressive disease more accurately than RECIST at every established threshold.
- 5 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (22) , 4541-4557
Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRAS G12D Inhibitor Treatment
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, primarily because of late-stage diagnosis and limited treatment options. Zinc homeostasis is markedly dysregulated in PDAC, and this dysregulation can be probed by administering a secretagogue to stimulate zinc secretion (SSZS) in the exocrine pancreas and imaging with a zinc-sensitive MRI probe. This study demonstrated the potential of SSZS-MRI for sensitive detection, monitoring treatment response, and assessing recurrence after treatment withdrawal in PDAC. The approach relied on interrogating the pancreas, circumventing the challenge of locating small, elusive tumors. SSZS-MRI enabled PDAC detection by observing the unique zinc hypersecretory activity of the pancreas when malignancy was present. PDAC led to dysregulation of zinc transporters in both human and mouse pancreas. Combining secretagogues such as secretin and caerulein maximized zinc secretion and MRI signal in the pancreas. Notably, SSZS-MRI detected treatment responses to KRASG12D inhibition within 3 to 5 days and identified cancer recurrence as early as 1 day after treatment withdrawal. Additionally, secretagogue stimulation improved treatment responses and delayed recurrence in both treatment models. These findings suggest that SSZS-MRI could significantly enhance PDAC diagnosis and management, providing an imaging modality that can help optimize patient outcomes. Significance: Secretagogue-stimulated zinc secretion MRI is effective at detecting pancreatic cancer, monitoring treatment response, and determining cancer recurrence, offering a promising noninvasive imaging tool to improve patient management and outcomes.
- 5 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 85 (22) , 4541-4557
Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRAS G12D Inhibitor Treatment
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, primarily because of late-stage diagnosis and limited treatment options. Zinc homeostasis is markedly dysregulated in PDAC, and this dysregulation can be probed by administering a secretagogue to stimulate zinc secretion (SSZS) in the exocrine pancreas and imaging with a zinc-sensitive MRI probe. This study demonstrated the potential of SSZS-MRI for sensitive detection, monitoring treatment response, and assessing recurrence after treatment withdrawal in PDAC. The approach relied on interrogating the pancreas, circumventing the challenge of locating small, elusive tumors. SSZS-MRI enabled PDAC detection by observing the unique zinc hypersecretory activity of the pancreas when malignancy was present. PDAC led to dysregulation of zinc transporters in both human and mouse pancreas. Combining secretagogues such as secretin and caerulein maximized zinc secretion and MRI signal in the pancreas. Notably, SSZS-MRI detected treatment responses to KRASG12D inhibition within 3 to 5 days and identified cancer recurrence as early as 1 day after treatment withdrawal. Additionally, secretagogue stimulation improved treatment responses and delayed recurrence in both treatment models. These findings suggest that SSZS-MRI could significantly enhance PDAC diagnosis and management, providing an imaging modality that can help optimize patient outcomes. Significance: Secretagogue-stimulated zinc secretion MRI is effective at detecting pancreatic cancer, monitoring treatment response, and determining cancer recurrence, offering a promising noninvasive imaging tool to improve patient management and outcomes.